John P. O’Donnell

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Réville, Satenig Guler, Janelle Comita-Prevoir et al. · Nature Microbiology · 2017 · 262 citations

Bacterial Resistance, Antimicrobial Susceptibility, Health Sciences +12

Contribution by purines to the neurogenic response of the vas deferens of the guinea pig

Jeffrey S. Fedan, G. Kurt Hogaboom, John P. O’Donnell et al. · European Journal of Pharmacology · 1981 · 240 citations

Animal Physiology, Neurophysiology, Medicine +12

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink et al. · The Lancet Infectious Diseases · 2023 · 238 citations

Antimicrobial Susceptibility, Antimicrobial Stewardship, Antibiotics +12

Rational design of a new antibiotic class for drug-resistant infections

Thomas F. Durand-Réville, Alita A. Miller, John P. O’Donnell et al. · Nature · 2021 · 134 citations

Antimicrobial Susceptibility, Antibiotics, Rational Design +8

(R)-, (S)-, and Racemic Fluoxetine N-Demethylation by Human Cytochrome P450 Enzymes

Jeannine M. Margolis, John P. O’Donnell, Dayna C. Mankowski et al. · Drug Metabolism and Disposition · 2000 · 132 citations